| P/E (FY) | — | Sales (TTM) | $2.09B |
| Earnings (TTM) | $424.9M | ROE | — |
| Net Margin | — | ROIC | — |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | — |
Qiagen provides sample-to-insight solutions that transform biological samples into molecular insights worldwide. It offers sample technology consumables such as nucleic acid stabilization and purification kits, silica membrane and magnetic bead technologies, and instruments for nucleic acid purification and quality control. The company also supplies immune response consumables including an interferon-gamma release assay for TB testing, and assays for oncology, prenatal testing, and detection of sexually transmitted disease.
| Market Cap | $9.17B | Trading Days | 5293 |
| 52W High | 57.81 |
| 52W Low | 32.53 |
| % Off High | −26.87% |
| YTD | −5.29% | 1Y | −16.46% |
| 3Y | −9.23% | 5Y | −17.15% |
| 10Y | 82.36% | Since incept. (ann.) | 6.07% |
| Ann. Volatility (1Y) | 34.18% | Ann. Volatility (3Y) | 27.65% |
| Sharpe (1Y) | −0.37 | Sharpe (3Y) | 0.03 |
| Max Drawdown (1Y) | −41.38% | Max Drawdown (3Y) | −41.38% |
| Beta (3Y, vs SPY) | 0.53 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| KYMR | Kymera Therapeutics, Inc. | $8.73B | — |
| HALO | HALOZYME THERAPEUTICS, INC. | $9.90B | 32.6 |
| RGEN | REPLIGEN CORP | $8.20B | 169.0 |
| APGE | Apogee Therapeutics, Inc. | $8.14B | — |
| IMVT | Immunovant, Inc. | $7.99B | — |
| PCVX | Vaxcyte, Inc. | $7.88B | — |
| KRYS | Krystal Biotech, Inc. | $10.74B | 53.3 |
| TECH | BIO-TECHNE Corp | $11.28B | 156.7 |
| IBRX | ImmunityBio, Inc. | $7.30B | — |
| CGON | CG Oncology, Inc. | $6.41B | — |
| EXEL | EXELIXIS, INC. | $14.20B | 20.3 |
| SRRK | Scholar Rock Holding Corp |
| $5.92B |
| — |